Rtw Biotech Regulatory News (RTW)

For

 111,002,846 votes

Against

 0 votes

Withheld

18,361,456 votes

For

110,999,214 votes

Against

3,632 votes

Withheld

18,361,456 votes

For

323,388,353 votes

Against

0 votes

Withheld

18,365,088 votes

For

323,388,353 votes

Against

3,632 votes

Withheld

18,361,456 votes

For

323,391,985 votes

Against

0 votes

Withheld

18,361,456 votes

For

111,002,846 votes

Against

0 votes

Withheld

18,361,456 votes

For

110,999,214 votes

Against

3,632 votes

Withheld

18,361,456 votes

For

111,002,846 votes

Against

0 votes

Withheld

18,361,456 votes

Resolution 9

IT WAS RESOLVED That the Company be and is hereby authorised, in accordance with section 315 of the Companies (Guernsey) Law, 2008, as amended (the "Companies Law"), subject to the Listing Rules made by the United Kingdom Financial Conduct Authority and all other applicable legislation and regulations, to make market acquisitions (within the meaning of section 316 of the Companies Law) of its own Ordinary Shares (as defined in the Company's Articles) which may be cancelled or held as treasury shares, provided that:

i. the maximum number of Ordinary Shares authorised to be purchased under this authority shall be 31,837,132 Ordinary Shares (being 14.99 per cent. of the Ordinary Shares in issue as at the Latest Practicable Date, excluding any treasury shares);

ii. the minimum price (exclusive of expenses) which may be paid for an Ordinary Share is US$0.01;

iii. the maximum price (exclusive of expenses) which may be paid for an Ordinary Share shall be not more than an amount equal to the higher of (a) 5 per cent. above the average mid-market value of the Ordinary Shares on the regulated market where the repurchase is carried out for the five Business Days (as defined in the Company's Articles) prior to the day the purchase is made and (b) the higher of (i) the price of the last independent trade and (ii) the highest current independent bid price, in each case on the regulated market where the purchase is carried out; and such authority to expire on the date which is 15 months from the date of passing of this resolution or, if earlier, at the end of the Annual General Meeting of the Company to be held in 2023 (unless previously renewed, revoked or varied by the Company by ordinary resolution), save that the Company may make a contract to acquire Ordinary Shares under this authority before its expiry which will or may be executed wholly or partly after its expiration and the Company may make an acquisition of Ordinary Shares pursuant to such a contract.

Resolution 10

IT WAS RESOLVED That the Company's name be changed from "RTW Venture Fund Limited" to "RTW Biotech Opportunities Ltd" with immediate effect.

Application will be made to the Guernsey Registry to register the change of name. Such change will take effect upon receipt of the confirmation from the Guernsey Registry. A further announcement will be made at that time.

Responses to investors' questions will be posted on the Company's website after the AGM.

¹ The Company notes that the voting rights adjustments under Article 6 and Article 23 of the Company's Articles of Incorporation were used in respect of resolutions 3, 4, and 5, but this did not affect the outcome of the shareholder vote.

RTW Investments, LP

+44 (0)20 7959 6361

Woody Stileman, Managing Director

Krisha McCune, Director, Client Service

Buchanan

+44 (0)20 7466 5107

Charles Ryland

Henry Wilson

George Beale

Numis

+44 (0)20 7260 1000

Freddie Barnfield

Nathan Brown

Euan Brown

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

Kieran Millar

Cadarn Capital

+44 (0) 73 6888 3211

David Harris

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885